rhiniti
common
condit
affect
approxim
symptom
rhiniti
often
ignor
frequent
associ
common
cold
disappear
spontan
howev
rhiniti
disrupt
sleep
neg
impact
daili
function
also
lead
rhinosinus
asthma
otiti
media
learn
econom
burden
rhiniti
estim
approxim
usd
per
patient
year
unit
total
healthcar
expenditur
associ
allerg
rhiniti
million
usd
korean
intranas
herbal
therapi
includ
ointment
drop
spray
wide
use
treat
rhiniti
east
asian
herbal
ointment
clinic
use
korean
medicin
improv
nasal
symptom
associ
rhiniti
prepar
addit
sophora
radix
glycyrrhiza
radix
et
rhizoma
korean
medicin
herbal
prescript
hht
consist
coptidi
rhizoma
cortex
phellodendri
scutellaria
radix
gardenia
experiment
studi
suggest
hht
effect
regul
cytokin
includ
nitric
oxid
prostaglandin
interleukin
il
tumour
necrosi
factor
tnf
effect
suppress
eosinophil
deriv
hht
assum
reduc
variou
symptom
caus
nasal
inflamm
includ
nasal
congest
rhinorrhea
sneez
safeti
effect
human
thoroughli
investig
aim
current
studi
investig
safeti
effect
clinic
feasibl
treatment
nasal
symptom
associ
rhiniti
prospect
observ
clinic
studi
conduct
woosuk
korean
medicin
medic
center
south
korea
novemb
march
protocol
approv
institut
review
board
woosuk
korean
medicin
medic
center
identifi
code
wsoh
irb
regist
nation
clinic
trial
registri
clinic
research
inform
servic
registr
id
primari
registri
world
health
organ
intern
clinic
trial
registri
platform
http
written
inform
consent
obtain
studi
particip
studi
design
summaris
tabl
irrespect
rhiniti
subtyp
follow
criteria
requir
order
qualifi
inclus
studi
age
year
continu
nasal
symptom
week
total
nasal
symptom
score
tnss
tnss
congest
score
patient
pregnant
current
plan
becom
pregnant
breastfeed
exclud
studi
obtain
inform
consent
data
demograph
characterist
medic
histori
acquir
physic
examin
conduct
assess
elig
particip
studi
patient
includ
studi
visit
studi
site
consecut
week
total
visit
manufactur
dispensari
pharmaci
woosuk
korean
medicin
medic
center
consist
medicin
herb
coptidi
rhizoma
g
phellodendri
cortex
g
scutellaria
radix
g
gardenia
fructu
g
sophora
radix
g
glycyrrhiza
radix
et
rhizoma
g
dilut
agent
oliv
oil
l
yellow
wax
gl
borneol
g
menthol
g
qualiti
control
data
present
figur
patient
provid
instruct
use
medicin
cotton
swab
time
day
week
patient
use
usag
diari
record
number
applic
drug
complianc
assess
everi
visit
base
diari
studi
period
particip
permit
take
medic
relat
rhiniti
common
cold
andor
influenza
aggrav
symptom
rescu
medicin
prescrib
particip
guid
report
use
medic
studi
period
usag
concomit
treatment
assess
everi
visit
outcom
measur
detail
tabl
primari
outcom
tnss
qualiti
life
questionnair
rqlq
nasal
endoscopi
index
total
serum
immunoglobulin
e
ige
level
immunolog
factor
deriv
nasal
lavag
fluid
nlf
also
examin
tnss
assess
everi
visit
total
time
nasal
caviti
assess
use
nasal
endoscopi
index
everi
photograph
anterior
nasal
caviti
obtain
use
harmoni
ent
machin
kasama
ent
co
ltd
complet
studi
photograph
independ
score
base
nasal
endoscopi
index
assess
two
outcom
assessor
involv
examin
blind
patient
inform
total
serum
ige
level
measur
first
final
visit
identifi
rhiniti
subtyp
chang
inflammatoryimmunolog
condit
nlf
sampl
first
final
visit
accord
hentschel
cytokin
includ
interferon
ifn
rant
mig
measur
nlf
use
commerci
cytometr
bead
array
human
cytokin
chemokin
kit
bd
bioscienc
accord
manufactur
safeti
studi
vital
sign
particip
examin
everi
visit
inform
advers
event
ae
provid
particip
ae
potenti
relat
examin
associ
measur
outcom
assess
demograph
characterist
express
mean
sd
continu
variabl
frequenc
percentag
categor
variabl
pair
test
wilcoxon
test
use
determin
signific
chang
treatment
valu
repres
mean
differ
md
confid
interv
ci
miss
valu
handl
use
last
observ
carri
forward
method
level
signific
set
p
analys
perform
independ
statistician
use
sa
version
sa
institut
inc
decemb
march
patient
enrol
studi
two
subsequ
drop
prior
administr
two
drop
examin
total
patient
complet
studi
patient
analys
miss
data
imput
patient
drop
examin
patient
characterist
summaris
tabl
final
analysi
set
includ
men
women
mean
age
year
prior
commenc
trial
patient
rhiniti
year
year
year
year
year
addit
patient
experienc
continu
rhiniti
symptom
day
day
day
day
rhiniti
accompani
allerg
diseas
patient
patient
allerg
rhiniti
vasomotor
rhiniti
patient
rhiniti
eosinophilia
syndrom
nare
patient
infecti
rhiniti
mean
frequenc
applic
time
per
day
maximum
minimum
frequenc
applic
time
per
day
respect
treatment
progress
mean
tnsss
exhibit
signific
improv
baselin
figur
end
week
md
ci
correspond
data
subsequ
follow
week
ci
week
ci
week
ci
addit
nasal
symptom
exhibit
signific
improv
visit
figur
signific
differ
found
baselin
week
nasal
congest
ci
rhinorrhea
ci
itch
ci
sneez
ci
treatment
progress
mean
score
exhibit
signific
improv
compar
baselin
figur
end
week
md
ci
correspond
data
subsequ
follow
week
ci
week
ci
week
ci
subgroup
score
also
significantli
improv
rel
baselin
score
figur
differ
observ
baselin
week
subgroup
score
includ
activ
ci
practic
problem
ci
nasal
symptom
ci
eye
symptom
ci
symptom
ci
nasal
endoscopi
index
significantli
improv
week
treatment
compar
baselin
figur
end
week
md
ci
correspond
data
subsequ
follow
week
ci
week
ci
week
ci
specif
treatment
significantli
improv
nasal
mucou
membran
colour
ci
ci
ci
week
compar
baselin
figur
total
serum
ige
level
examin
decreas
baselin
differ
statist
signific
ci
p
level
nlf
significantli
increas
examin
compar
baselin
ci
p
howev
differ
found
level
immun
cytokin
addit
nlf
level
chemokin
significantli
reduc
end
point
studi
compar
baselin
tabl
patient
report
follow
ae
common
cold
influenza
headach
gastriti
enter
throat
discomfort
cold
gastric
cramp
seriou
advers
event
report
studi
period
patient
take
medic
patient
take
medic
patient
take
aspirin
prevent
cardiovascular
diseas
patient
take
medic
patient
take
finasterid
alopecia
addit
patient
took
herbal
medicin
day
gastric
discomfort
patient
took
paracetamol
tablet
headach
among
particip
taken
common
cold
drug
among
patient
taken
herbal
medicin
day
common
cold
patient
taken
oseltamivir
tamiflu
day
type
influenza
patient
taken
oseltamivir
tamiflu
pseudoephedrin
hydrochlorid
levodropropizin
bepotastin
salicyl
last
visit
type
influenza
anoth
patient
taken
pseudoephedrin
hydrochlorid
prednisolon
bepotastin
salicyl
paracetamol
day
common
cold
exclud
particip
taken
common
cold
medic
data
collect
remain
particip
present
tabl
present
studi
treatment
gradual
reduc
tnsss
nasal
congest
rhinorrhea
itch
sneez
improv
score
subgroup
score
includ
activ
practic
problem
nasal
symptom
eye
symptom
symptom
moreov
treatment
improv
inferior
nasal
concha
nasal
mucou
membran
intranas
surfac
colour
collect
find
suggest
improv
nasal
symptom
qualiti
life
allevi
intranas
mucos
condit
treatment
tend
reduc
total
serum
ige
reduct
statist
signific
current
studi
includ
rhiniti
patient
irrespect
presenc
absenc
allerg
rhiniti
includ
particip
normal
serum
ige
level
prior
treatment
studi
need
evalu
effect
allerg
rhiniti
patient
elev
serum
ige
level
immunomodulatori
effect
play
import
role
pathogenesi
allerg
rhiniti
via
regulatori
present
studi
level
significantli
higher
treatment
assum
regul
express
result
activ
regulatori
cell
suppress
immun
respons
associ
rhiniti
current
studi
chemokin
investig
includ
member
famili
basic
chemoattract
polypeptid
significantli
reduc
nlf
treatment
previou
studi
suggest
nlf
recruit
activ
neutrophil
contribut
inflamm
coincid
nasal
symptom
observ
rhiniti
may
play
role
develop
nasal
allerg
inflamm
elev
nlf
allerg
rhiniti
addit
level
involv
leucocyt
recruit
allerg
nasal
mucosa
also
elev
allerg
rhiniti
observ
suggest
regul
intranas
inflammatori
allerg
reaction
reduc
chemokin
level
summari
might
improv
nasal
symptom
suppress
leucocyt
nasal
mucosa
involv
inflammatori
allerg
reaction
result
improv
intranas
condit
studi
first
clinic
trial
evalu
effect
topic
herbal
ointment
rhiniti
patient
effect
assess
via
subject
questionnair
object
nasal
endoscopi
index
immun
biomark
level
nlf
reflect
characterist
nasal
caviti
reaction
topic
administr
potenti
therapeut
agent
seriou
ae
occur
current
studi
suggest
safe
treatment
period
week
interestingli
common
cold
frequent
observ
ae
studi
notabl
studi
conduct
winter
season
typic
higher
preval
differ
viral
infect
includ
respiratori
syncyti
viru
influenza
viru
coronaviru
infect
throughout
present
studi
improv
rhiniti
observ
treatment
although
common
cold
influenza
might
aggrav
rhiniti
symptom
current
studi
sever
limit
hypothesis
may
allevi
nasal
symptom
associ
rhiniti
base
prior
experi
therefor
studi
includ
rhiniti
patient
regardless
rhiniti
phenotyp
endotyp
rhiniti
phenotyp
endotyp
numer
divers
encompass
mani
differ
patholog
treatment
thu
treatment
effect
may
differ
patient
differ
rhiniti
phenotyp
therefor
futur
studi
clinic
trial
need
incorpor
differenti
rhiniti
phenotyp
endotyp
design
addit
durat
action
highli
molecularli
standardis
characteris
drug
often
reliabl
estim
base
pharmacokinet
optim
dosag
regimen
determin
base
human
pharmacolog
howev
durat
action
herbal
prepar
ointment
use
present
studi
easili
assess
due
presenc
multipl
bioactiv
compound
patient
present
studi
instruct
appli
ointment
time
per
day
base
prior
experi
thu
pharmacokinet
studi
need
determin
appropri
dosag
regimen
third
limit
present
studi
comparison
treatment
group
placebo
group
aim
studi
explor
feasibl
clinic
conduct
randomis
control
trial
thu
investig
safeti
effect
without
control
select
inform
bia
uncontrol
studi
might
overestim
effect
test
intervent
moreov
symptom
season
ar
perenni
rhiniti
includ
vasomotor
rhiniti
nare
fluctuat
therefor
appropri
control
group
essenti
assess
effect
therefor
futur
randomis
control
trial
need
confirm
effect
particip
includ
present
studi
treat
alon
evalu
clinic
effect
rhiniti
patient
consid
efficaci
term
improv
tnsss
score
nasal
endoscopi
index
immun
biomark
level
well
complet
absenc
seriou
ae
patient
rhiniti
treatment
feasibl
clinic
practic
safe
option
treatment
rhiniti
studi
first
examin
clinic
effect
find
suggest
intranas
administr
safe
control
clinic
trial
warrant
determin
efficaci
manag
rhiniti
symptom
author
declar
conflict
interest
